Skip to main content

AlgoNomics, Genmab Collaborate on Antibody Research

NEW YORK (GenomeWeb News) – Belgium’s AlgoNomics has entered into a research partnership with the Danish antibody company Genmab, the company announced today.
AlgoNomics plans to assist Genmab with detailed structural analysis of its fully human antibody molecules and antibody scaffolds, including Genmab’s new small, stable, modified antibody technology, UniBody.
Combined with experimental data, the companies believe structural information gleaned from AlgoNomics’ antibody structure database and structure-based protein and peptide design platform, Tripole, may reveal new functional or therapeutic properties for Genmab’s products.
AlgoNomics said that it will be eligible for Genmab research funding and milestone payments under the agreement, but did not disclose any other financial details or additional information about potential therapeutics.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.